LYMPHOID NEOPLASIA Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity
نویسندگان
چکیده
1Department of Immunology, Center of Biostructure Research, Medical University of Warsaw, Warsaw; 2Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw; 3Department of Lymphoproliferative Diseases, Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology, Warsaw; 4Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw; 5Department of Clinical Hematology, Military Medical Institute, Warsaw; and 6Department 3, Institute of Physical Chemistry, Polish Academy of Sciences, Warsaw, Poland
منابع مشابه
Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity.
Unresponsiveness to rituximab treatment develops in many patients prompting elucidation of underlying molecular pathways. It was recently observed that rituximab-resistant lymphoma cells exhibit up-regulation of components of the ubiquitin-proteasome system (UPS). Therefore, we investigated in more detail the role of this system in the regulation of CD20 levels and the influence of proteasome i...
متن کاملSAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
PURPOSE The CD38 cell surface antigen is expressed in diverse hematologic malignancies including multiple myeloma, B-cell non-Hodgkin lymphoma (NHL), B-cell chronic lymphocytic leukemia, B-cell acute lymphoblastic leukemia (ALL), and T-cell ALL. Here, we assessed the antitumor activity of the anti-CD38 antibody SAR650984. EXPERIMENTAL DESIGN Activity of SAR650984 was examined on lymphoma, leu...
متن کاملrILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
PURPOSE Ofatumumab is an anti-CD20 antibody recently approved for treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL); it mediates much stronger complement-dependent cytotoxicity (CDC) than rituximab. Human CD59, a key membrane complement regulator that inhibits CDC, is highly expressed in B-cell malignancies and its upregulation is an important determinant of...
متن کاملDirect effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives.
The anti-CD20 monoclonal antibody rituximab is the backbone of treatment for the B-cell malignancies non-Hodgkin lymphoma and chronic lymphocytic leukemia. However, there is a wide variability in response to rituximab treatment, and some patients are refractory to current standard therapies. Rituximab kills B cells by multiple mechanisms of action, including complement-dependent cytotoxicity an...
متن کاملCancer Therapy: Preclinical rILYd4, a Human CD59 Inhibitor, Enhances Complement- Dependent Cytotoxicity of Ofatumumab against Rituximab- Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia
Purpose: Ofatumumab is an anti-CD20 antibody recently approved for treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL); it mediates much stronger complementdependent cytotoxicity (CDC) than rituximab. Human CD59, a key membrane complement regulator that inhibits CDC, is highly expressed in B-cellmalignancies and its upregulation is an important determinant of ...
متن کامل